Physician profile
Robert Casper Wiggins
NPI 1386006872
$138,250.97
in general payments reported to CMS, 2019-2025
7 companies · $85K in 2025
The $85K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $111 · 2023: $27K · 2024: $27K · 2025: $85K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $89K · Consulting Fee: $20K · Travel and Lodging: $17K · Honoraria: $7,780 · Food and Beverage: $4,515 · Education: $19.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $89,292.50 |
| Consulting Fee | $19,580.00 |
| Travel and Lodging | $16,953.63 |
| Honoraria | $7,780.00 |
| Food and Beverage | $4,514.84 |
| Education | $19.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $61,515.22 | 2023-2025 | Gocovri, Gocovri, Apokyn |
| Abbvie INC. | $56,957.25 | 2023-2025 | Duopa |
| Acadia Pharmaceuticals INC | $19,221.18 | 2024-2025 | Nuplazid |
| Supernus Pharmaceuticals, INC. | $180.53 | 2023-2025 | Qelbree |
| Medtronic, INC. | $144.00 | 2025 | Percept PC Brainsense |
| Biogen, INC. | $121.89 | 2024 | |
| Boston Scientific Corporation | $110.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wiggins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.